A novel Bruton's tyrosine kinase inhibitor JDB175 shows potent efficacy to suppress central nervous system lymphoma

Patients with central nervous system (CNS) lymphoma face limited treatment options and poor treatment outcomes, emphasizing the urgent need for effective therapeutic strategies. One limiting factor contributing to the suboptimal efficacy is the inadequate penetration of most treatment drugs across t...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Yong, Li, Xue, Jiang, Ning, Wei, Xiawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625055/
https://www.ncbi.nlm.nih.gov/pubmed/37929016
http://dx.doi.org/10.1002/mco2.424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625055/
https://www.ncbi.nlm.nih.gov/pubmed/37929016
http://dx.doi.org/10.1002/mco2.424

Ejemplares similares